Subcutaneous apomorphine reduces OFF time and dyskinesias and improves quality of life in Parkinson’s disease (PD) – 5-year follow-up of patients in Greece
Objective: To evaluate the long-term efficacy of subcutaneous apomorphine (APO) injection and APO infusion in controlling motor fluctuations and dyskinesias and the impact on quality…FBOX07 mutation with juvenile parkinsonism and behavioral disorders
Objective: FBX07 (PARK15) mutations cause juvenile parkinsonism with autosomal ressesive inheritance. Juvenile parkinsonism, pyramidal tract signs and atypical symptoms such as dystonia, chorea, behavioral disturbances,…Self-perception of daily performance in relation to motor performance in advanced Parkinson’s disease – Case studies
Objective: To evaluate Parkinson's disease (PD) patients' perception of their performance of daily living (ADL) in their “ON” and “OF” stages and relate them to…Duloxetine, a serotonin and norepinephrine reuptake inhibitor, reduces daily OFF time in Parkinson’s disease
Objective: To evaluate efficacy of duloxetine on motor symptoms in Parkinson's disease (PD) patients with wearing-off in an open label trial. Background: Duloxetine, a serotonin…A web resource on levodopa-induced dyskinesia (LID) genetics
Objective: Establish a web resource summarizing literature-based genetic information on levodopa-induced dyskinesia in an easily accessible and consistent way. Background: Levodopa induced dyskinesia (LID) is…Real-life data on the use of levodopa carbidopa intestinal gel in Parkinson’s disease
Objective: To report our institution's initial clinical experience with initiation and management of levodopa carbidopa intestinal gel (LCIG) formulation Duopa®. Background: Carbidopa/levodopa intestinal gel (LCIG)…AntiParkinsonian treatment patterns and motor complications among patients with Parkinson´s disease in Estonia
Objective: To evaluate pharmacological treatment patterns in patients with Parkinson´s disease (PD), prevalence of motor complications, and factors associated with them. Background: Levodopa is the…Neuromelanin imaging is useful for monitoring disease progression in Parkinson’s disease and PARK2
Objective: Using neuromelanin (NM)-MRI, we analyzed whether disease severity and MF is associated with the degree of dopaminergic neuronal degeneration in the substantial nigra compacta…Levodopa induced dyskinesia and nicotinergic α4β2 acetylcholin receptor density: A multi-tracer imaging study
Objective: We investigated α4β2 acetylcholin receptor (nAChR) density in subjects with Parkinson's disease (PD) with and without levodopa-induced dyskinesia (LID) and its correlation with dopaminergic…Effects of safinamide in patients with Parkinson’s disease measured by Parkinson’s KinetiGraphTM
Objective: To objectively evaluate the effects of Safinamide in patients with Parkinson's (PD) by using the Parkinson's KinetiGraphTM (PKG), a newly developed tool for graphically…
- « Previous Page
- 1
- …
- 37
- 38
- 39
- 40
- 41
- …
- 44
- Next Page »